Compare Realty Income Corp (O) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Realty Income Corp trades at $65.09 (market cap $60.60B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2× Realty Income Corp's market cap, and Realty Income Corp pays a 5% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| O | VRTX | |
|---|---|---|
Market Cap | $60.60B | $122.33B |
Sector | Real Estate | Health |
52-Week High | $67.56 | $529.59 |
52-Week Low | $55.93 | $366.54 |
Enterprise Value | $90.40B | $117.07B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $64.99, down 1.1% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported revenue of $5.75B in 2025 with a net income margin of 19.05%, though recent quarterly EPS results have missed expectations. Analyst consensus is a Hold with a $67.43 price target, and the stock offers a consistent dividend, recently paying $0.27 per share.
Outlook remains mixed; growth via partnerships and a high 5.14% yield are positives, but elevated P/E of 53.43 and consecutive EPS misses pose risks. Investors should weigh the reliable income stream against valuation concerns and interest rate sensitivity.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
